1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Anaplastic lymphoma kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030

Anaplastic lymphoma kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030

  • May 2020
  • 100 pages
  • ID: 5893087
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Anaplastic lymphoma kinase-Non Small Cell Lung Cancer (ALK-NSCLC)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted ALK NSCLCepidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Understanding
Lung cancer mainly begins in the lungs, and it may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases.
There are mainly two types of lung cancer small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. In these subtypes adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma..
There are several genetic mutations identified to play a major role in the progression of this indication. Mutations in EGFR, KRAS, and ALK are mutually exclusive in patients with NSCLC, and the presence of one mutation instead of another can influence response to targeted therapy. There are several mutations associated with NSCLC but the most common are EGFR, KRAS, ROS-1, BRAF, C-Met, PD-L1 expression and others. Among all the mutations ALK mutation accounted for approximately 4% of the total cases of NSCLC.
ALK-positive mutation was discovered in 2007. ALK-positive lung cancers harbor a gene rearrangement referred to as the EML4-ALK fusion gene, compose a subset of tumors for which medical treatment has expanded rapidly (along with survival) in the past few years. An ALK mutation is diagnosed by molecular profiling of a sample of the tumor. It’s important in doing this testing that an adequate supply of tissue from either a lung biopsy or lung cancer surgery is obtained. Researchers are also looking at ways to determine if an ALK mutation is present before genetic testing is done, or could substitute for genetic testing.

Epidemiology Perspective
The ALK NSCLC epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The ALK NSCLC epidemiology data are studied through ALK NSCLC possible division to give a better understanding of the Disease scenario in the 7MM.
The disease epidemiology covered in the report provides historical as well as forecasted Anaplastic lymphoma kinase-Non Small Cell Lung Cancer epidemiology [segmented as Total Incidence of NSCLC Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total ALK-NSCLC cases, and Treated Patient Pool of ALK-NSCLC] scenario of Anaplastic lymphoma kinase-Non Small Cell Lung Cancer in the 7MM covering the United States, EU5 countries (Germany, France, Italy , Spain, and the United Kingdom), and Japan from 2017 to 2030.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Detailed Epidemiology Segmentation
• Total incident population of NSCLC in the 7MM was assessed to be 4,84,726 in 2017.
• Total incident population of ALK NSCLC in the 7MM was assessed to be 22,197 in 2017.
• The total incident cases of ALK NSCLC in the United States were found to be 8,449 in 2017 which is expected grow during the study period, i.e., 2017–2030.
• In case of EU-5, Germany hold upto around 29% of the EU-5 Patient population. Japan accounts upto 5,000 ALK-Positive cases in 2017.

Scope of the Report
• The ALK NSCLC report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
• The ALK NSCLC Report and Model provide an overview of the risk factors and global trends of ALK NSCLC in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan).
• The report provides insight about the historical and forecasted patient pool of ALK NSCLC in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of ALK NSCLC.
• The report provides the segmentation of the ALK NSCLC epidemiology by total Incidence of NSCLC in the 7MM.
• The report provides the segmentation of the ALK NSCLC epidemiology by total diagnosed cases of NSCLC patients by Stages in the 7MM.
• The report provides the segmentation of the ALK NSCLC epidemiology by Histology in the 7MM.
• The report provides the segmentation of the ALK NSCLC epidemiology by Treated Patient Pool of ALK NSCLC in the 7MM.

Report Highlights
• 11-Year Forecast of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer epidemiology
• 7MM Coverage
• Total Incident Cases of Non-Small Cell Lung Cancer
• Incident Cases according to segmentation: Histology, ALK-NSCLC
• Treated cases of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer

KOL-Views
We interview, KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over ALK NSCLC scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anaplastic lymphoma kinase-Non Small Cell Lung Cancer ?
• What are the key findings pertaining to the Anaplastic lymphoma kinase-Non-Small Cell Lung Cancer epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of Anaplastic lymphoma kinase-Non-Small Cell Lung Cancer across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Anaplastic lymphoma kinase-Non-Small Cell Lung Cancer?

Reasons to buy
The Anaplastic lymphoma kinase-Non Small Cell Lung Cancer Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Anaplastic lymphoma kinase-Non Small Cell Lung Cancer market
• Quantify patient populations in the global Anaplastic lymphoma kinase-Non Small Cell Lung Cancer market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Anaplastic lymphoma kinase-Non Small Cell Lung Cancer therapeutics in each of the markets covered
• Understand the magnitude of Anaplastic lymphoma kinase-Non Small Cell Lung Cancer population by its severity
• The Anaplastic lymphoma kinase-Non Small Cell Lung Cancer epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Anaplastic lymphoma kinase-Non Small Cell Lung Cancer Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
Total Incident cases of ALK NSCLC in the United States was assessed to be 8,449 in 2017, and are expected to increase during the study period. Among the European 5 countries, Germany had Incident population of ALK NSCLC. On the other hand, Spain had the lowest incident cases of ALK NSCLC in 2017.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on